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Hyperinsulinemic-euglycemic clampterized by elevated rates of cardiac fatty acid utilization resulting in reduced
efﬁciency and cardiomyopathy. One potential therapeutic approach is to limit the uptake and oxidation of
fatty acids. The aims of this study were to determine whether a quantitative reduction in heart-type fatty
acid binding protein (FABP3) normalizes cardiac substrate utilization without altering cardiac function.
Transgenic (FABP3+/−) and wild-type (WT) littermates were studied following low fat (LF) or high fat (HF)
diets, with HF resulting in obese, insulin-resistant mice. Cardiovascular function (systolic blood pressure, %
fractional shortening) and heart dimension were measured at weaning and every month afterward for
3 mo. During this period cardiovascular function was the same independent of genotype and diet.
Catheters were surgically implanted in the carotid artery and jugular vein for sampling and infusions in
mice at 4 mo of age. Following 5 d recovery, mice underwent either a saline infusion or a
hyperinsulinemic-euglycemic clamp (4 mU kg-1 min-1). Indices of long chain fatty acid and glucose
utilization (Rf, Rg; μmol g wet weight
-1 min-1) were obtained using 2-deoxy[3H]glucose and [125I]-15-ρ-
iodophenyl)-3-R,S-methylpentadecanoic acid. FABP3+/− had enhanced cardiac Rg compared with WT during
saline infusion in both LF and HF. FABP3+/− abrogated the HF-induced decrement in insulin-stimulated
cardiac Rg. On a HF diet, FABP
+/− but not WT had an increased reliance on fatty acids (Rf) during insulin
stimulation. In conclusion, cardiac insulin resistance and glucose uptake is largely corrected by a reduction
in FABP3 in vivo without contemporaneous deleterious effects on cardiac function.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Chronic high fat feeding results in obesity, insulin resistance and
elevated rates of fatty acid oxidation. These changes are facilitated by
an increase in the transcription and translation of numerous fatty acid
related genes [1,2]. Heart-type fatty acid binding protein-3 (FABP3) is
one such protein that facilitates the movement of fatty acids in cardiac
muscle [3–5]. Acting as a cytosolic fatty acid shuttle, it reversibly binds
and moves fatty acids from the plasma membrane into storage or to
the mitochondria for oxidation [6]. The protein is abundantly
expressed, and modulated in a variety of physiologic and pathologic
states. It is thought to play a key role in fatty acid utilization and
numerous pharmaceutical inhibitors for the protein are presently at
various stages of development [7,8].niversity Drive NW, University
+1 403 270 0737.
ll rights reserved.We have previously reported that partial deletion of FABP3
attenuated obesity-associated insulin resistance in a murine model
and analyzed the effect of the deletion on systemic glucose disposal
and skeletal muscle glucose uptake [9]. Absolute genetic deﬁciency of
FABP3 has not been reported in humans, and total abrogation of FABP3
function is an unrealistic therapeutic goal. A mouse model with a
partial reduction of FABP3 is a more relevant model to test the role of
FABP3 in the pathogenesis of insulin resistance and as a therapeutic
target. Moreover, it is clear that abnormalities in myocardial energy
metabolism play an important role in the genesis of cardiac
dysfunction in insulin resistance [10]. Accordingly, it is essential to
determine the effects of a partial decrease in FABP3 level on cardiac
substrate utilization and cardiac function.
The high-fat fed C57BL/6J mouse is obese and insulin resistant
compared to low fat fed mice of the same strain [11]. Since these mice
are resistant to the development of atherosclerosis, any abnormality
arising in the high-fat fed condition can likely be attributed to
metabolic abnormalities rather than obstructive coronary artery
disease [12]. It was hypothesized that reduction of FABP3 expression
587J. Shearer et al. / Biochimica et Biophysica Acta 1782 (2008) 586–592would inhibit heart fatty acid utilization and increase the dependence
of the heart on glucose as a substrate.
2. Methods
2.1. FABP3+/− mice
All procedures performed were approved by the Vanderbilt
University Animal Care and Use Committee. Generation of FABP3+/−
mice has been previously described [9]. Mice lacking FABP3 were
originally produced on a 129/Balb/c background and backcrossed for
at least 10 generations to C57BL/6J. Mice carrying the FABP3 null
transgene were subsequently bred and following a 3-week weaning
period, littermates were separated by gender, maintained in micro-
isolator cages and fed either a low fat (LF) or high fat (HF) diet ad
libitum. Energy density of the LF diet (5001 Laboratory Rodent Diet,
Purina, Richmond, IN) was 28.5% (234.0 g/kg) of energy as protein,
13.5% (45.0 g/kg) as fat and 58.0% (499.0 g/kg) as carbohydrate. In
comparison, the HF diet (Custom Diet F3282; Bio-Serv; Frenchtown,
NJ) contained15.2% (197.4 g/kg) of energyas protein, 59.4% (358.0 g/kg)
as fat and 24.5% (358.2 g/kg) as carbohydrate. The primary source of fat
in this dietwas lard.Micewere studied at∼4mo of age. Genotyping for
the FABP3 null transgene was performed on genomic DNA obtained
from a tail biopsy as described previously [9]. Four groups ofmicewere
studied: WT mice fed low fat (LF-WT) or HF (HF-WT) diet and mice
absent one FABP3 allele fed low fat (LF-FABP3+/−) or HF (HF-FABP3+/−)
diet.
2.2. Cardiac function
Transthoracic echocardiography was performed after weaning
(1 mo) and at monthly intervals to 4 mo as previously described
[13,14]. To examine the effects of FABP+/− with prolonged high-fat
feeding, cardiac function was also examined in a separate cohort of
mice at 8 mo of age on HF.
Echo images were acquired using a Sonos 5500 (Agilent; Andover,
MA) with a 15 MHz high frequency linear transducer. Prior to
initiation of the study, the mice were trained on 2 separate occasions
over 1–2 d. 2-D targeted M-Mode echocardiographic images were
obtained at the level of the papillary muscles from the parasternal
short-axis view. Measurements were made on screen using the
digitally recorded M-mode tracings using the leading-edge technique.
The fractional shortening FS%, a measure of LV systolic performance,
was calculated from M-mode derived parameters.
Basal measurements of blood pressure were performed after mice
were acclimated to the tail cuff plethysmography apparatus during 3
sessions on successive days to reduce stress-related perturbations and
artifacts in measurement. Systolic and diastolic pressures were
measured over 3 sequential determinations and recorded as absolute
values and deviates, with re-measurement when excessive variance
relative to strain-based controls was present.
2.3. Isotopic analogues
Glucose and long chain fatty acid (LCFA) tracers employed in the
present study were 2-deoxy[3H]glucose ([3H]DG; New England
Nuclear; Boston, MA) and [125I]-15-(ρ-iodophenyl)-3-R,S-methylpen-
tadecanoic acid ([125I]BMIPP). BMIPP was a kind gift from Dr. Russ
Knapp, Oak Ridge International Laboratories (Oak Ridge, TN). Radio-
iodination was performed according to a standard protocol. Brieﬂy,
BMIPPwas heated in the presence of Na125I solution (740MBq/200 μl),
propionic acid, and copper (II) sulphate. Na2S2O3 was then added, and
the organic phasewas ether extracted and sequentially back extracted
with saturated NaHCO3 and water. After evaporation, the [125I]BMIPP
was solubilized for infusion using sonication into ursodeoxycholic
acid.2.4. Euglycemic-hyperinsulinemic clamps
Surgical catheterization of the left common carotid artery and right
jugular vein was performed as previously described [15,16]. Animals
were individually housed after surgery and lines were ﬂushed daily
with ∼20 μl of saline containing 200 U/ml of heparin and 5 mg/ml of
ampicillin. Experiments were performed following a post-operative
recovery period of ∼5 days, which was sufﬁcient for bodyweight to be
restored to within 10% of pre-surgery body weight. On the day of the
study, conscious, unrestrained mice were placed in a ∼1 L plastic
container lined with bedding and fasted for 5 h. Micro-Renathane
(0.033 in OD) tubing was connected to the catheter leads and infusion
syringes. Following this, a baseline (t=-90 min) arterial blood sample
(150 μL) was drawn for the measurement of glucose, hematocrit, and
plasma insulin and LCFA. The remaining red blood cells were washed
with 0.9% heparinized saline and reinfused. Mice were then infused
with saline alone (n=30) or with insulin (4 mU kg-1 min-1; n=30). To
maintain euglycemia during insulin experiments, arterial blood
glucose (∼5 μl; HemoCue; Mission Viejo, CA) was measured at
∼10min intervals and glucose (50%) was administered into the venous
catheter. Mice also received saline-washed red blood cells from a
donor mouse as needed in order to maintain hematocrit within 5% of
initial hematocrit. Following a 90 min equilibration period (t=0 min),
an arterial blood sample (150 μL) was obtained and processed as the
baseline blood sample. At t=5 min, a bolus of [3H]DG and [125I]BMIPP
was administered to obtain indices of glucose and LCFA uptake and
clearance. At t=7, 10, 15, and 20 min, arterial blood (∼50 μL) was
sampled in order to determine blood glucose, plasma [3H]DG and
[125I]BMIPP. At t=30 min, a ﬁnal arterial blood sample was obtained
(150 μL) and processed as the baseline blood sample with additional
blood for themeasurement of [3H]DG and [125I]BMIPP. Micewere then
anesthetized and the heart was quickly excised, rinsed in saline, and
rapidly freeze clamped in liquid nitrogen. Samples were stored at
-80 °C until subsequent analysis.
2.5. Tissue FABP3 content
Total FABP3 protein content was determined on cardiac muscles
homogenized in M-PER lysis buffer (Pierce, Rockford, IL) supplemen-
ted with protease (Pierce) and phosphatase (Sigma) inhibitor cock-
tails. After centrifugation (30 min at 4500 g) pellets were discarded
and supernatants were retained for protein determination using a
BCA protein assay kit (Pierce). Proteins (20 μg) were separated on a
4–12% Bis-Tris SDS-PAGE gel (Invitrogen) and then transferred to a
PVDF membrane. Membranes were blocked, probed with rabbit anti-
FABP3 (1:3000), and then incubated with anti-rabbit conjugated with
horseradish peroxidase (1:20,000; Pierce, Rockford, IL). The mem-
branes were then exposed to chemiluminescent substrate and
images were taken using the VersaDoc imaging system (Bio-Rad).
In order to conﬁrm equal protein loading and transfer, membranes
were stripped and reprobed with monoclonal anti-glyceraldehyde-
3-phosphate dehydrogenase (GAPDH, 1:4000, Abcam) and then
incubated with anti-mouse conjugated with horseradish peroxidase
(1:20,000, Amersham). Densitometry was performed using ImageJ
software (NIH).
2.6. Plasma measures
Immunoreactive insulin was assayed with a double antibody
method [17]. Non-esteriﬁed fatty acids (NEFA) were measured
spectrophotometrically (Wako NEFA C kit, Wako Chemicals Inc.,
Richmond, VA). [125I]BMIPP and [3H]DG were measured in plasma
and tissues as previously described [18]. Brieﬂy, plasma was counted
for [125I]BMIPP using a Beckman Gamma 5500 counter (Beckman
Instruments, Fullerton, CA). Following this, the plasma sample was
deproteinized in Ba(OH)2 and ZnSO4 and subsequently centrifuged. 3H
Fig. 1. Total FABP3 content in the heart muscle in WT and FABP3+/− fed either a LF or
an HF (60% of kcal from lipid) for 12 wk. Immunoblotting was performed to measure
total FABP3 protein content. FABP3 levels were normalized to GADPH content. Order
of loading on the immunoblot follows the graphical data. Densitometry data are
means±SE, n=7 per group. ⁎Indicates pb0.05 between genotype within diet,
†Indicates pb0.05 between diets.
Table 2
Effects of genotype and diet on cardiovascular parameters at baseline, 12 wk or 35 wk
on either a low or high fat diet
Baseline Low fat, 3 mo High fat, 3 mo
WT SBP (mmHg) 110±4 118±4 112±5
HR (bpm) 590±34 642±14 723±9
FS% 56.5±1.9 48.3±1.9 46.9±0.9
IVSd (cm) 0.072±0.003 0.096±0.001 0.097±0.002
LVIDd (cm) 0.265±0.009 0.285±0.012 0.316±0.011
LVPWd (cm) 0.079±0.003 0.095±0.003 0.097±0.004
IVSs (cm) 0.146±0.005 0.167±0.004 0.167±0.003
LVIDs (cm) 0.116±0.008 0.149±0.011 0.171±0.009
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2900TR Liquid Scintillation Analyzer (PerkinElmer, Boston, MA).
Following determination of tissue 125I radioactivity, tissues were
homogenized in 0.5% PCA and centrifuged for 20 min. Supernatants
were then neutralized using 5 M KOH and 3H radioactivity was
determined by liquid scintillation counting.
2.7. Calculations
Glucose clearance (Kg) and metabolic (Rg) indices were calculated
from the accumulation of [3H]DG phosphate ([3H]DGP) and the
integral of the plasma [3H]DG concentration following a [3H]DG bolus
[19,20]. The relationships are deﬁned as:
Kg = ½3HDGP
h i
m
tð Þ=
Z t
0
½3HDG
h i
p
dt ð1Þ
Rg = Kg × G½ p ð2Þ
The subscripts p andm refer to mean arterial plasma and total muscle
accumulation respectively. The measurement of Rg has been described
earlier [20]. In an analogousmanner LCFA clearance (Kf) andmetabolic
(Rf) indices were calculated from the accumulation of [125I]BMIPP in
muscle and the integral of the plasma [125I]BMIPP concentration
following the tracer bolus.
Kf = ½125IBMIPP
h i
m
tð Þ=
Z t
0
½125IBMIPP
h i
p
dt ð3Þ
Rf = Kg × LCFA½ p ð4Þ
[[125I]BMIPP]m is the [125I]BMIPP in the cell, [125I]BMIPP]p is the [125I]
BMIPP present in the plasma. The measurements of Rf and Kf have
been described earlier [18,21].
2.8. Statistical analyses
A two-way analysis of variance (ANOVA) was performed to detect
statistical differences (pb0.05). Differences within the ANOVA, were
determined using a Tukey post hoc test. All data are reported as
means±standard error of the mean (SEM).
3. Results
3.1. Baseline characteristics
A total of 30 male and 30 female mice were used in metabolic
studies. Sex was equally distributed within a group and there were
14–16 animals per group. Changes in bodymass over time in each diet
are reported in Table 1. For cardiac function studies a minimum of 9
mice in each genotype and dietary condition were studied. For both
sets of experiments, no qualitative gender effects were observed, and
accordingly, data from male and female mice within a treatment
group are considered together. The basic phenotype of FABP3+/− miceTable 1
Body mass of wild-type (WT) and fatty acid binding protein heterozygotes (FABP3+/−)
animals used in metabolic studies at baseline (post-weaning, no dietary intervention)
and following 6, 9, or 12 wk of a low or high fat diet
Diet Genotype n Baseline 6 wk 9 wk 12 wk
Low fat WT 14 19±1 22±1 24±1 26±2
FABP3+/− 16 21±1 24±1 25±1 26±2
High fat WT 16 21±1 26±1 32±1⁎ 40±2⁎
FABP3+/− 14 21±1 27±2 31±1⁎ 39±2⁎
Animal sex was equally distributed between groups.
Data represent means±SE.
⁎ Indicates signiﬁcant difference (pb0.05) between diets at a given time point.has been reported previously [9]. Total body mass of both WT and
FABP3+/−mice are greater in HF (40±2, 39±2 g) compared to LF (26±2,
26±2 g). Fasting plasma glucose in LF are 8.5±0.3 and 8.7±0.1 mM for
WT and FABP3+/−, respectively. High fat feeding caused hyperglycemia
in WT (10.6±0.3 mM) but not FABP3+/− (8.3±0.4 mM). Fasting plasma
NEFA for LF-WT, LF-FABP3+/−, HF-WT and HF-FABP3+/− were 1.3±0.1,
1.7±0.1, 1.8±0.1 and 1.6±0.1 mM respectively. Fasting levels of NEFA
were signiﬁcantly different only between LF-WTand HF-WT (pb0.05).
High fat feeding also resulted in fasting hyperinsulinemia regardless of
genotype (pb0.05) with values of 21±10, 19±10, 68±10 and 71±
10 mU/ml for LF-WT, LF-FABP3+/−, HF-WT and HF-FABP3+/−.
The effects of heterozygous deletion and diet on FABP3 protein
level in cardiac muscle are shown in Fig. 1. On a standard LF dietLVPWs (cm) 0.116±0.007 0.127±0.007 0.129±0.005
FABP+/− SBP (mmHg) 116±4 116±3 112±5
HR (bpm) 652±16 643±13 742±7
FS% 51.9±1.0 46.5±1.1 47.1±1.2
IVSd (cm) 0.077±0.002 0.099±0.001 0.103±0.003
LVIDd (cm) 0.262±0.005 0.300±0.007 0.311±0.005
LVPWd (cm) 0.076±0.002 0.096±0.003 0.104±0.003
IVSs (cm) 0.144±0.004 0.170±0.003 0.178±0.005
LVIDs (cm) 0.126±0.003 0.161±0.005 0.164±0.005
LVPWs (cm) 0.106±0.003 0.129±0.004 0.139±0.007
SBP, systolic blood pressure; HR, heart rate; FS%, fractional shortening; IVSd,
interventricular septal thickness in diastole; LVIDd, LV end-diastolic dimension;
LVPWd, LV posterior wall thickness in diastole; IVSs, interventricular septal thickness
in systole; LVIDs, LV end-systolic dimension; LVPWs, LV posterior wall thickness in
systole. Data represent means±SE. n=8–10 mice/treatment.
Fig. 3. Glucose utilization (Rg) in cardiac muscle during saline infusion (top panel) and a
euglycemic-hyperinsulinemic clamp (4 mU/kg/min) (bottom panel). Wild type (WT)
and heterozygous mice (FABP+/−) are shown. ⁎Indicates pb0.05 HF vs. LF fed within a
genotype, †pb0.05 WT vs. FABP+/− within a diet. All data are reported as means±SEM,
n=7–8 mice/group.
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FABP3 protein (relative to GAPDH, 1.0±0.24 vs. 0.68±0.06 arbitrary
units, pb0.05). High fat feeding increased heart FABP3 level by ∼2x
(2.04±0.025) and heterozygous deletion on a high fat diet blunted this
increase (0.97±0.08, all differences pb0.05).
3.2. Cardiovascular function
There was no signiﬁcant difference among genotypes with respect
to systolic blood pressure, ventricular function or ventricular dimen-
sions at baseline, or after 3 months of either LF or HF (Table 2). Systolic
blood pressure and % fractional shortening did not differ within a
genotype after 3 months of the speciﬁed diet or at intermediate points
(Fig. 2). Comparable dimensions and systolic blood pressure indicate
comparable loading conditions for the measurement of systolic
function.
Cardiac functionwas also examined in an additional cohort of mice
at 8 mo of age on HF (n=8 WT, n=5 FABP3+/−). At this time, body mass
was 54±2.7 and 55±2.8 for WT and FABP3+/− respectively. The only
signiﬁcant difference between groups was a moderate decrement in
basal systolic function in FABP3+/− mice compared with WT (WT FS%
52.4±3.1%; FABP3+/− FS% 44.7±1.4%, pb0.001). Thus, at 8 months
FABP3+/− increased LV end-systolic dimensionwithout altering LV wall
thickness or end-diastolic diameter.
3.3. Plasma measures and glucose infusion rates
Plasma measures and glucose infusion rates during clamps have
been previously reported [9] and are brieﬂy summarized here. Mean
insulin concentrations during insulin clampswere ∼60 μU/ml in LF fed
mice. High fat feeding resulted in ∼two-fold higher clamp insulin
concentrations (i.e. ∼120 μU/ml). Infusion of insulin resulted in a
suppression of LCFA from baseline values in LF fed mice. In HF mice,
LCFA were not suppressed signiﬁcantly by insulin. HF reduced GIR by
∼70% and ∼50% in WT and FABP3+/−, respectively, compared to the
respective LF fed mice of the same genotype.Fig. 2. A: Systolic blood pressure (SBP) (mmHg) and B: % fractional shortening (%FS) at
baseline (1 mo of age) and following 1, 2, 3 mo of either a LF or HF diet. No signiﬁcant
differences were noted between diet, age or genotype. Data represent means±SE.
n=8–10 mice/treatment.3.4. Metabolic indices of cardiac glucose and fatty acid metabolism
Cardiac Rg measurements are shown in Fig. 3. Basal cardiac Rg in
LF-WT was not different from rates in HF-WT. LF-FABP3+/− mice had a
Ntwo-fold increase in basal cardiac Rg when compared to LF-WT. Basal
Rg in HF-FABP3+/− was reduced compared to LF-FABP3+/−. Cardiac Rg
was increased during insulin clamps in all groups. In relation to LF, HF
resulted in insulin resistance and a reduction in cardiac Rg (Fig. 3).
FABP3+/− prevented this decline as there was no difference between Rg
in LF-FABP3+/− and HF-FABP3+/− mice.Fig. 4. Fatty acid utilization (Rf) in cardiac muscle during saline infusion (top panel) and
a euglycemic-hyperinsulinemic clamp (4 mU/kg/min, bottom panel). Wild type (WT)
and heterozygous mice (FABP3+/−) are shown. ⁎Indicates pb0.05 high fat vs. low fat fed
within a genotype. All data are reported as means±SEM, n=7–8 mice/group.
Fig. 5. Relative rates of cardiac glucose (Kg) and fatty acid (Kf) clearance during a
euglycemic-hyperinsulinemic clamp across genotype and treatment. Kg is depicted by
the closed symbols (●) while the open symbols (○) represent Kf. All data are reported as
means±SEM, n=7–8 mice/group. ⁎Indicates pb0.05 HF vs. LF fed within a genotype,
†pb0.05 WT vs. FABP3+/− within a diet.
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elevated in HF-WT compared to LF-WT. However, there was no such
increase in HF-FABP3+/− in relation to LF-FABP3+/− due to the high
variance in the LF-FABP3+/− measure of Rf. Here, differences in NEFA
levels between genotypes may be a contributing factor. Cardiac Rf was
increased in HF-WT during insulin clamps compared to LF-WT. As in
the basal state, HF feeding induced an increase in cardiac Rf, which
was alleviated by partial deletion of FABP3, as rates were not different
between HF-FABP3+/− and LF-FABP3+/−. Kg and Kf are indices of glucose
and LCFA ﬂux that are calculated independently of their respective
concentrations. Results of Kg and Kf during insulin clamps are shown
in Fig. 5. Cardiac Kg and Kf were decreased and increased, respectively
in HF-WT compared to LF-WT. A partial reduction in FABP3+/− blunted
these effects of HF feeding.
4. Discussion
Insulin resistance results in cardiac dysfunction due to an
oversupply of FFA that drives changes in metabolism, gene expression
and function [22–24]. One therapeutic approach to correct perturbed
metabolism in insulin-resistant tissue is to limit the uptake and
oxidation of fatty acids [25,26]. In the present study, HF feeding was
successfully employed to induce obesity and insulin resistance in WT
and FABP3+/− mice. Although only HF-WT developed hyperglycemia
and hyperlipidemia, both genotypes were insulin resistant as
evidenced by a reduction in whole body glucose infusion rates during
a hyperinsulinemic-euglycemic clamp. HF-WT resulted in a ∼70%
impairment in glucose infusion rates compared to a 50% reduction in
HF-FABP3+/− [9]. Together these results suggest that a small reduction
in FABP3+/−maymitigate the development of insulin resistance caused
by HF feeding.
A partial reduction in FABP3 increased basal cardiac glucose
utilization in LF fed animals. High fat feeding blunted this response
indicating that the genetic reductionwas not sufﬁcient to restore total
glucose utilization in an obese, insulin-resistant state. Insulin-
stimulated glucose utilization was reduced in HF-WT animals but
not HF-FABP3+/− compared to the respective LF controls. Together,
these results show that altering fatty acid utilization by targeting or
inhibiting FABP3+/− levels may be a viable means to counter perturbed
substrate ﬂux seen in obesity and insulin resistance. These results are
in line with previous studies showing both ablation and a hetero-
zygous reduction in FABP3 are protective towards dietary-induced
insulin resistance [6,9]. However, a potential caveat is that the direct
tissue speciﬁc effects of FABP3 cannot be readily distinguished from
secondary consequences of changes in systemic metabolism, although
from a therapeutic standpoint this distinction may not be critical.
To examinewhether a reciprocal relationship between glucose and
fatty acid utilization existed in FABP3+/− mice, I125-BMIPP, a partially
metabolizable fatty acid tracer was employed. Basal fatty acidutilization was greater in WT-HF compared to WT-LF. Increases in
fatty acid utilization with obesity are well known and result from an
increased efﬁciency of fatty acid uptake [27]. This increased efﬁciency
also contributes to the accumulation of intracellular triacyglycerides
which are implicated in the etiology of metabolic dysfunction [28–30].
Upon insulin stimulation,WT-HF showed the hypothesized, reciprocal
change in substrate utilizationwith a decrease in glucose uptake and a
corresponding increase in fatty acid utilization. This ﬁnding is
important to the insulin-resistant heart as inhibiting fatty acid uptake
and oxidation are established anti-anginal approaches [31]. Ranola-
zine, trimetazidine and perhexiline are agents that inhibit fatty acid
utilization and are known to improve both the symptoms from and
decrease the frequency of angina pectoris [25].
When the combined results of cardiac glucose and fatty acids
utilization are analyzed in terms of substrate clearance rather than
uptake, results show that FABP3+/− mice do not have signiﬁcantly
altered basal rates. This is in agreement with the ﬁndings of Luiken et
al [32,33], in which heterozygous deletion of FABP3 was described as
“permissive” on fatty acid uptake using giant vesicle techniques.
However, when exposed to high fat feeding, this balance is disrupted
and only partially restored by lowering FABP3 levels. Beyond its role in
directly regulating substrate utilization, FABP3 has been shown to play
important roles in intracellular binding, targeting, signal transduction
and gene expression [34]. Of interest, Murphy and colleagues [6] have
shown FABP3 to target speciﬁc fatty acids towards β-oxidation or
esteriﬁcation. A lack of FABP3 in cardiac muscle differentially affects
the fate and handling of both saturated and polyunsaturated fatty
acids with 20:4n-6 directed towards phospholipid fractions and 16:0
directed to β-oxidation. By mediating the availability of fatty acids
available for oxidation, FABP3 is concluded to play an important role in
fatty acid mediated signal transduction in the heart, consistent with,
or potentially extending, the effects expected from the “Randle cycle.”
Additional results show cardiac FABP3 protein levels to change in
response to HF feeding. High fat feeding resulted in more than a
doubling of cardiac FABP3 levels regardless of genotype suggesting
this protein plays a pivotal role in shifting metabolism to favor fatty
acids. Between genotypes studied here, germline deletion of a single
allele decreased FABP3 protein level compared to WT in both LF and
HF. However, the magnitude of the difference was less than 50%.
FABP3 is a prominent element in a cohort of highly regulated
metabolic genes linked to speciﬁc transcription factors in the heart
[35,36], and this attenuated decrease was potentially due to induced
counter-regulatory transcriptional effects. Indeed, previous studies
conﬁrm FABP3 levels are highly variable, with protein levels changing
in concert with metabolic demands. This is evident in the fetal heart,
where the expression of FABP3 increases rapidly following birth,
allowing the heart to transition from glucose to fatty acids as a
predominant energy source [37]. In addition, weight loss, chronic
exercise training and omega-3 supplemented diets are all known to
increase levels of FABP3 in skeletal muscle [38–42].
As a strong interdependence exists between heart metabolism and
function, we determined the effects of diet-induced insulin resistance
and FABP3+/− on cardiac function at numerous time points throughout
the experiment. Echocardiographic assessment was conducted at
baseline and following 4, 8, and 12 wk on each respective diet,
spanning the metabolic evaluation reported. Results demonstrated
that this level of quantitative decrease in FABP3, with either a LF or HF
diet, did not alter basal heart function or dimension in conditions of
comparable afterload (systolic blood pressure) at 12 wk. This extends
previous studies that have shown either no change or only slight
cardiac dysfunctionwith high fat feeding [43,44]. The lack of change in
cardiac function with insulin resistance in the present study at 4 mo
may be due to the circumscribed duration of the dietarymanipulation.
Indeed, prolonged high-fat feeding (8 mo) in FABP3+/− was associated
with a mild decrement LV end-systolic dimension without altering LV
wall thickness or end-diastolic size.
591J. Shearer et al. / Biochimica et Biophysica Acta 1782 (2008) 586–592This contrasts with data published in the null mutation of FABP3,
which resulted in morphologic cardiac hypertrophy, with increased
thickness of both the septum and ventricle [3]. While null mutations
of FABP3 appear to be deleterious to heart function, these results show
no effect of a heterozygous mutation for several months, suggesting
that a full complement of the protein is not continuously necessary
under normal conditions. This is essential if FABP3 is to be a credible
therapeutic target for metabolic manipulation, or if interventions
targeted at other FABP's have a lesser but detectable effect on FABP3.
This study examined mice absent a single FABP3 allele. This creates a
model withmore physiological and pathophysiological relevance than
mice with a full knockout of the FABP3 gene, as the latter has not been
reported in humans. Of course, insulin resistance is also often
accompanied by associated cardiovascular alterations such as hyper-
tension, myocardial infarction and congestive failure. The applicability
of present observations to these states requires further investigation.
Limitations of the present study include our inability to distinguish
between the effects of high fat feeding from obesity and insulin
resistance. Diet alone is known to inﬂuence cardiac metabolism,
independent of obesity. In addition, cardiac metabolism was only
assessed at a single time point (4 mo) as the tracer technique
employed requires animal euthanasia, and the catheter technique
carries substantially increases mortality in old mice. In contrast,
cardiac function was serially measured over time. Lastly, plasma
samples obtained from the animals were of limited volume. As such,
other measures of interest including leptin and adiponectin could not
be assessed.
In conclusion, results of the present study show FABP3 to have a
central role in cardiac fuel selection and utilization in both health and
obesity. Acting in a permissive capacity, FABP3 levels are highly
variable and dependent on metabolic demands. Here we show insulin
resistance to cause perturbed cardiac substrate utilization in vivo, but
that the severity of impairment is limited in the context of reduced
FABP3 content. Importantly, this metabolic change is not associated
with changes in basal cardiac dimension or systolic function.
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